Laser-assisted subepithelial keratectomy for low to high myopia and astigmatism.
OBJECTIVE
To evaluate the safety and efficacy of laser-assisted subepithelial keratectomy (LASEK) for the treatment of low to high myopia and astigmatism.


METHODS
Solo private practice, Mountain View, California, USA.


METHODS
Laser-assisted subepithelial keratectomy was performed in 146 eyes of 83 consecutive patients with myopia or myopic astigmatism using a VISX Star S2 excimer laser (72 eyes) or a Nidek EC-5000 excimer laser (74 eyes). The mean preoperative myopic spherical equivalent was -5.32 diopters (D) (range -1.25 to -14.38 D). Data were collected prospectively with a follow-up of 1 to 12 months. Outcome measurements included uncorrected visual acuity (UCVA), manifest refraction, best spectacle-corrected visual acuity (BSCVA), corneal haze, and complications.


RESULTS
After 6 and 12 months, no eye lost 2 or more lines of BSCVA. After 6 months, the UCVA was 20/20 in 57% of eyes and 20/40 or better in 96%. After 12 months, it was 20/20 in 56% of eyes and 20/40 or better in 96%. No eye developed corneal haze that affected visual acuity. There were no serious or vision-threatening complications.


CONCLUSIONS
Laser-assisted subepithelial keratectomy was safe and effective in treating a wide range of myopia and astigmatism. The potential advantages of LASEK over laser in situ keratomileusis (LASIK) include the elimination of stromal flap complications and greater choice in patient selection. The disadvantages include varying degrees of pain for 2 days and blurry vision for several days postoperatively.
Shahinian
Lee
L
75553.72@compuserve.com
D001251:Astigmatism / Q000503:physiopathology / Q000534:rehabilitation / Q000601:surgery*; D005139:Eyeglasses; D006801:Humans; D020731:Keratomileusis, Laser In Situ; D054018:Lasers, Excimer; D009216:Myopia / Q000503:physiopathology / Q000534:rehabilitation / Q000601:surgery*; D018903:Photorefractive Keratectomy; D012449:Safety; D013997:Time Factors; D014792:Visual Acuity